A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis

Autor: Shefner, Jeremy M, Cudkowicz, Merit E, Hardiman, Orla, Cockroft, Bettina M, Lee, Jacqueline H, Malik, Fady, Meng, Lisa, Rudnicki, Stacy A, Wolff, Andrew A, Andrews, Jinsy A, Van Damme, Philip, Korngut, Lawrence, Johnston, Wendy, O'Connell, Colleen, Grant, Ian, Turnbull, John, Shoesmith, Christen, Zinman, Lorne, Botez, Stephan, Genge, Angela, Dionne, Annie, Couratier, Philippe, Attarian, Shahram, Pouget, Jean, Camu, William, Desnuelle, Claude, Salachas, Francois, Corcia, Philippe, Meyer, Thomas, Petri, Susanne, Ludolph, Albert, Calvo, Andrea, Lunetta, Christian, Silani, Vincenzo, van den Berg, Leonard, de Carvalho, Mamede, Mora Pardina, Jesus, Young, Carolyn, Al-Chalabi, Ammar, Radunovic, Aleksander, Hanemann, Clemens, Ladha, Shafeeq, Goyal, Namita, Ravits, John, Lewis, Richard, Joyce, Nanette, Oskarsson, Bjorn, Katz, Jonathan S, So, Yuen, Quan, Dianna, Felice, Kevin, Bayat, Elham, Boylan, Kevin, Benatar, Michael G, Tuan, Vu, Glass, Jonathan, Sufit, Robert, Bodkin, Cynthia, Swenson, Andrea, Statland, Jeffrey, Maragakis, Nicholas, Berry, James, Brown, Robert, Salameh, Johnny, Goutman, Stephen, Newman, Daniel S, Guliani, Gaurav, Maiser, Samuel, Pestronk, Alan, Hayat, Ghazala, Pattee, Gary, Cohen, Jeffrey, Brooks, Benjamin, Bedlack, Richard, Caress, James, Mitsumoto, Hiroshi, Lange, Dale, Bradshaw, Deborah, Kolb, Stephen J, Karam, Chafic, Khoury, Julie, Goslin, Kimberly, Simmons, Zachary, Mc Cluskey, Leo, Heiman-Patterson, Terry, Donofrio, Peter, Heitzman, Daragh, Harati, Yadollah, Jackson, Carlayne, Phillips, Lawrence, Weiss, Michael, Nance, Christopher, Sultan, Shumaila, Barkhaus, Paul

Publikováno v: Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, Taylor & Francis, 2019, 20 (7-8), pp.584-594. ⟨10.1080/21678421.2019.1612922⟩

OBJECTIVE: To assess the efficacy of tirasemtiv, a fast skeletal muscle troponin activator, vs. placebo in patients with amyotrophic lateral sclerosis. Methods: VITALITY-ALS (NCT02496767) was a multinational, double-blind, randomized, placebo-control

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::968405046683d6e5a5203613e68ec401
https://doi.org/10.1080/21678421.2019.1612922

Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial.

Autor: Howard, James F., Nowak, Richard J., Wolfe, Gil I., Freimer, Miriam L., Vu, Tuan H., Hinton, John L., Benatar, Michael, Duda, Petra W., MacDougall, James E., Farzaneh-Far, Ramin, Kaminski, Henry J., Barohn, Richard, Dimachkie, Mazen, Pasnoor, Mamatha, Farmakidis, Constantine, Liu, Tina, Colgan, Samantha, Benatar, Michael G., Bertorini, Tulio, Pillai, Rekha

Publikováno v: JAMA Neurology; May2020, Vol. 77 Issue 5, p582-592, 11p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Lack of effect of Miller Fisher sera/plasmas on transmitter release from PC12 cells

Autor: Benatar, Michael G ^a, Willison, Hugh J ^b, Vincent, Angela ^{a, *}

Publikováno v: In Journal of Neuroimmunology 1997 80(1):1-5